affecting the physician prescribing decision included safety (96%), efficacy (90%), and cost (86%) of drug choice while the patients viewed that efficacy (86%), convenient dosage (53%), and safety (42%) of a drug were their main concerns. About eight out of ten patients reported that the sources of information for pain management were from specialists, friends/family, GPs and TV/Radio. Nevertheless, most patients were not proactively discussing the potential risks associated with prescription of NSAIDs with their doctors. CONCLUSIONS: Different concerns and information communicated by doctors may affect how it is perceived by patients. Effective patient education is essential to encourage a two-way communication between physician-patient to minimize the negative outcomes and maximize the quality of care. Health-related quality of life (HRQL) and its impact upon productivity have not been well documented among hemophilia patients, nor among their caregivers. This study of hemophilia patients with inhibitors assessed patient and family caregiver productivity and the impact of patient HRQL.
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recorded, of which 10,047 (95%) were in public or not for profit hospitals. In the public sector, 37 hospitals (i.e. 10% of all public health care facilities) managed 50% of the caseload. There were 269 admissions for ITP-related splenectomy, mainly in the public sector (91%). Altogether 3612 patients in the public sector required 9360 admissions or 2.80 in-patient admissions per patient per year. In the private sector, 150 patients required 508 stays (3.4 hospital stays/patient/year). Based on these results, the mean charge was €3653 per patient in public hospitals, and €3177 per patient in private hospitals. The mean charge per patient in public hospitals for ITP-related splenectomy was €6367. These costs did not include expensive drugs, in particular immunoglobulins or rituximab, which are excluded from the DRGs reimbursement scheme in France and can result in extra billing. CONCLUSIONS: Administrative databases allow the estimation of the burden of ITP for hospitals. ITP and ITPrelated splenectomy were managed mostly in the public sector. Splenectomy increased the cost per patient twofold. The cost of expensive drugs to treat ITP must be evaluated in a separate study. (Krenov 2006) . Faster inactivation of recombinant B domain-deleted factor VIII (BDD-rFVIII) could affect efficacy during prophylaxis, potentially leading to increased risk for breakthrough bleeds and higher FVIII utilization. The objective of this analysis was to use real world data to determine whether patients treated with BDD-rFVIII had higher annual FVIII utilization than matched patients treated with full-length rFVIII (FL-rFVIII). METHODS: Retrospective analysis of a large, US specialty pharmacy database was conducted using 2006/2007 data. Patients who were not receiving Immune Tolerance Therapy, had at least six months of prescription activity, and did not switch brands or treatment regimens were selected. BDD-rFVIII patients were matched with up to 5 FL-rFVIII patients based on treatment regimen (on-demand and prophylaxis), hemophilia severity and age. The annualized number of international units (IU) dispensed per kilogram was compared between both rFVIII groups using a Wilcoxon Matched Pairs Test. Subgroup analysis was performed by treatment regimen. RESULTS: Twenty-two BDD-rFVIII patients met the inclusion criteria and were matched to 104 FL-rFVIII patients. Median annual IU/kg consumed for all BDDrFVIII and FL-rFVIII patients was 3630 and 3054 respectively (p = 0.20). Subgroup analysis showed a statistically significant difference observed when comparing patients on a prophylactic Abstracts A647
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